Cairn Therapeutics
Thursday, June 06, 2024
Oncology
Company Presentation Theater 1
Cairn Therapeutics, Inc. is a pharmaceutical company with a mission to help patients beat cancer. Founded in 2016, Cairn is developing its lead candidate, CT-262, a first-in-its-class treatment for a broad array of solid and hematological tumors. Cairn holds the exclusive worldwide license to CT-262, which was invented at Scripps Research Institute using unique medicinal chemistry to create a highly potent agent that preferentially activates in cancer cells. In vitro and in vivo animal oncology studies have shown CT-262 to produce markedly better efficacy and surprisingly low toxicological effects compared to current first-line therapies in these nonclinical models.
v
Company Website:
http://www.cairntherapeutics.com
Lead Product in Development:
CT-262
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Company HQ City
Greenville
Company HQ State
DE
Company HQ Country
United States
CEO/Top Company Official
Scott Evangelista
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())